Cargando…

Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence

Deregulated BCR-ABL oncogenic activity leads to transformation, oncogene addiction and drives disease progression in chronic myeloid leukemia (CML). Inhibition of BCR-ABL using Abl-specific kinase inhibitors (TKI) such as imatinib induces remarkable clinical responses. However, approximately only le...

Descripción completa

Detalles Bibliográficos
Autor principal: Burchert, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930845/
https://www.ncbi.nlm.nih.gov/pubmed/24500518
http://dx.doi.org/10.1007/s11899-013-0196-8